APOE and Alzheimer disease: Thus, the current observed associations between APOE, BMI and plasma biomarkers may not be solely due to a confounding effect of BMI, but may also reflect other pathological processes associated with preclinical AD, since ε4 carriers are more likely on this trajectory.